42 related articles for article (PubMed ID: 11684864)
1. Inhibition of intrinsic thrombin generation.
Stief TW
Drug Target Insights; 2006; 1():5-10. PubMed ID: 21901053
[TBL] [Abstract][Full Text] [Related]
2. Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence.
Drago F; Gozzo L; Li L; Stella A; Cosmi B
Front Pharmacol; 2020; 11():579886. PubMed ID: 33041824
[TBL] [Abstract][Full Text] [Related]
3. How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved?
Stanciakova L; Dobrotova M; Holly P; Zolkova J; Vadelova L; Skornova I; Ivankova J; Samos M; Bolek T; Grendar M; Danko J; Kubisz P; Stasko J
Clin Appl Thromb Hemost; 2022; 28():10760296211070004. PubMed ID: 35225706
[TBL] [Abstract][Full Text] [Related]
4. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
Bombeli T; Raddatz-Mueller P; Fehr J
Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
[TBL] [Abstract][Full Text] [Related]
5. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
6. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Schinzel H; Bahlmann F; Peetz D; Savvidis S; Himmrich L; Klotz M
Med Klin (Munich); 2002 Apr; 97(4):193-203. PubMed ID: 11977574
[TBL] [Abstract][Full Text] [Related]
8. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
Ulander VM; Stenqvist P; Kaaja R
Thromb Res; 2002 Apr; 106(1):13-7. PubMed ID: 12165283
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.
Bombeli T; Raddatz Mueller P; Fehr J
Haemostasis; 2001; 31(2):90-8. PubMed ID: 11684864
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins in pregnancy.
Ensom MH; Stephenson MD
Pharmacotherapy; 1999 Sep; 19(9):1013-25. PubMed ID: 10610007
[TBL] [Abstract][Full Text] [Related]
11. D-dimer testing in pregnancy.
Eichinger S
Semin Vasc Med; 2005 Nov; 5(4):375-8. PubMed ID: 16302159
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
James AH; Brancazio LR; Ortel TL
Clin Adv Hematol Oncol; 2005 Mar; 3(3):187-97. PubMed ID: 16166990
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
